H.C. Wainwright lowered the firm’s price target on Phio Pharmaceuticals to $4 from $6 and keeps a Buy rating on the shares. The lowered price target reflects the dilutive effects of the private placement completed in December, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PHIO:
- Phio Pharmaceuticals announces new preclinical data on INTASYL
- Phio Pharmaceuticals files to sell 4.42M shares of common stock for holders
- Biotech Alert: Searches spiking for these stocks today
- Phio Pharmaceuticals announces exercise of warrants for $2.8M gross proceeds
- Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds